Last reviewed · How we verify
Yangxinshi
Yangxinshi, marketed by Shenyang Northern Hospital, is a drug with an unspecified mechanism and primary indication, currently generating unknown revenue. The key composition patent is set to expire in 2028, which may provide a competitive advantage by delaying generic competition. However, the lack of detailed clinical trial results and identified competitors poses a significant risk to its market position.
At a glance
| Generic name | Yangxinshi |
|---|---|
| Also known as | Yangxinshi |
| Sponsor | Shenyang Northern Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction (PHASE4)
- Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI (PHASE4)
- Yangxinshi Tablet Intervention for Exercise Capacity in Patients With Chronic Coronary Syndrome (PHASE4)
- Effect of Yangxinshi Tablet on Exercise Tolerance in Patients With Chronic Coronary Syndrome（MET STUDY） (PHASE4)
- Effects of Yangxinshi Pills on the Exercise Tolerance of the Patients With Coronary Heart Disease (PHASE2)
- the Effects of YangXinShi (YXS) on the Quality of Life and Exercise Tolerance in Patients With Chronic Heart Failure (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Yangxinshi CI brief — competitive landscape report
- Yangxinshi updates RSS · CI watch RSS
- Shenyang Northern Hospital portfolio CI